A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation.
No Thumbnail Available
Date
2005-01-14
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
PURPOSE: To evaluate Tocoferol monoglucoside (TMG), a water soluble vit. E. in a phase I trial, as a radiation protector in those undergoing hemi-body radiation for disseminated disease.
MATERIALS AND METHODS: Patients scheduled to receive modified hemi-body radiation were accrued for the study. Patients not only had disseminated skeletal disease but, were heavily pretreated Seven patients were accrued for the study. Patients received 1 and 2 gms of TMG. 30-40 minutes before hemibody radiation. A dose of 600 cGy was delivered on telecobalt equipment at mid plane. Immediate Toxicities were evaluated as well as response to pain.
RESULTS: All the seven patients underwent radiation uneventfully. There was no drug related toxicity. Pain relief was adequate.
CONCLUSION: Tocoferol monoglucoside an effective antioxidant with no significant acute toxicity, when administered in a dose of 1 or 2 gms per oral route. TMG being water-soluble can have global antioxidant and radio protective effects. This needs further clinical evaluation.
Description
Keywords
Citation
Huilgol NG, Nair CK, Merhotra P, Kagiya VT. A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation. Journal of Cancer Research and Therapeutics. 2005 Jan-Mar; 1(1): 38-40